PharmaCyte Biotech, Inc. (PMCB)
CIK 1157075 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 10.7M shares as of Sep 11, 2026 (10-Q).⊙
Cash runway
Self-funding
generates cash
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Long Term Warrant | 38.2M | not tagged | — | — |
| Series B Warrants | 8.8M | $0.95 | — | — |
| Short Term Warrant | 2.1M | not tagged | — | — |
| QCLS Common Stock | 889,865 | not tagged | — | — |
| QCLS Series H Warrant | 600,000 | $3.3713 | — | — |
| Series C Placement Agent Warrants | 560,000 | not tagged | — | — |
| First Warrant Issuance | 343,183 | $0.95 | — | — |
| Settlement Warrants | 313,067 | not tagged | — | — |
| Additional Warrants | not tagged | $0.95 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Sep 14, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 7.0M underlying shares, as reported Aug 31, 2025 (10-Q).
Rough fully diluted estimate: 17.7M = 10.7M O/S + 7.0M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed Sep 14, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 10.7M | Sep 11, 2026 |
| + Long Term Warrant (if exercised) | 38.2M | Apr 30, 2026 |
| + Series B Warrants (if exercised) | 8.8M | May 10, 2023 |
| + Short Term Warrant (if exercised) | 2.1M | Sep 30, 2025 |
| + QCLS Common Stock (if exercised) | 889,865 | Sep 30, 2025 |
| + QCLS Series H Warrant (if exercised) | 600,000 | Sep 2, 2025 |
| + Series C Placement Agent Warrants (if exercised) | 560,000 | Aug 19, 2025 |
| + First Warrant Issuance (if exercised) | 343,183 | May 16, 2025 |
| + Settlement Warrants (if exercised) | 313,067 | Oct 29, 2025 |
| Fully diluted estimate | 62.5M | +482.0% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $22.6Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 0 executed · 0 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full PMCB workspace